1198339-37-5

Basic information

• Product Name: 2-methylazetidine-1,2-dicarboxylic acid 1-tert-butyl ester
• CAS NO: 1198339-37-5
• Molecular Weight: 215.249
• Mol File: 1198339-37-5.mol

Chemical Properties

• CAS DataBase Reference: 2-methylazetidine-1,2-dicarboxylic acid 1-tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-methylazetidine-1,2-dicarboxylic acid 1-tert-butyl ester(1198339-37-5)
• EPA Substance Registry System: 2-methylazetidine-1,2-dicarboxylic acid 1-tert-butyl ester(1198339-37-5)

Safety Data

• Hazardous Substances Data: 1198339-37-5(Hazardous Substances Data)

Upstream product

• 1384745-52-1 (R)-2-methyl-azetidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 
• 1269460-89-0 C₁₆H₂₅NO₃ 
• 1269460-95-8 C₁₆H₂₄ClNO₂ 
• 1269460-98-1 C₁₆H₂₃NO₂ 
• 1384745-34-9 (1S,2S)-1-benzyl-N-(2-hydroxy-1-phenylethyl)-2-methylazetidine-2-carboxamide 
• 1384745-48-5 (S)-1-benzyl-2-methyl-azetidine-2-carboxylic acid methyl ester 
• 1384745-51-0 (S)-2-methyl-azetidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1391077-73-8 2-methylazetidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 
• 1391077-71-6 1-benzyl-2-methylazetidine-2-carboxylic acid ethyl ester 
• 1391077-69-2 2-[benzyl-(2-chloroethyl)amino]propionic acid ethyl ester 
• 449758-77-4 1-(tert-butoxycarbonyl)-2-methylazetidine-2-carboxylic acid 

Downstream Products

• 1363402-35-0 2-methylazetidine-1,2-dicarboxylic acid 1-tert-butyl ester 
• 959841-26-0 6-[3-({4-[(1-aminocyclopentyl)carbonyl]piperazin-1-yl}carbonyl)-4-fluorobenzyl]-4,5-dimethylpyridazin-3(2H)-one 
• 959839-61-3 (2R)-2-[(4-{5-[(4,5-Dimethyl-6-oxo-1,6-dihydropyridazin-3-yl)methyl]-2-fluorobenzoyl}piperazin-1-yl)carbonyl]-2-methylazetidinium trifluoroacetate 
• 959839-63-5 6-{4-fluoro-3-[(4-{[1-(isobutylamino)cyclopentyl]carbonyl}piperazin-1-yl)carbonyl]benzyl}-4,5-dimethylpyridazin-3(2H)-one trifluoroacetate 
• 1391078-74-2 C₂₉H₃₅N₃O₄S 
• 1391076-52-0 4-(benzothiazol-5-ylmethyl-{1-[2-(3,5-dimethylphenyl)acetyl]-2-methylazetidine-2-carbonyl}amino)butyric acid 
• 1391076-11-1 4-(benzofuran-6-ylmethyl-{1-[2-(3,5-dimethyl-phenyl)acetyl]-2-methyl-azetidine-2-carbonyl}amino)butyric acid 
• 1391073-47-4 1-[2-(3-iodo-phenyl)-acetyl]-2-methyl-azetidine-2-carboxylic acid (4-chloro-benzyl)-methyl-amide 
• 1391078-66-2 C₂₁H₂₂ClIN₂O₂ 
• 1391075-19-6 1-(2-(benzo[b]thiophen-2-yl)acetyl)-N-(4-chlorobenzyl)-N,2-dimethylazetidine-2-carboxamide 
• 1391075-01-6 1-(benzo[b]thiophene-3-carbonyl)-2-methyl-azetidine-2-carboxylic acid (4-chlorobenzyl)methylamide 
• 1391075-41-4 1-(benzofuran-5-carbonyl)-N-(4-chlorobenzyl)-N,2-dimethylazetidine-2-carboxamide 

Relevant articles and documents

Heterochiral Ala/(aMe)Aze sequential oligopeptides: Synthesis and conformational study

a-Amino acid residues with a ?,? constrained conformation are known to significantly bias the peptide backbone 3D structure. An intriguing member of this class of compounds is (aMe)Aze, characterized by an Na-alkylated four-membered ring and Ca-methylation. We have already reported that (S)-(aMe)Aze, when followed by (S)-Ala in the homochiral dipeptide sequential motif -(S)-(aMe)Aze-(S)-Ala-, tends to generate the unprecedented ?-bend ribbon conformation, as formation of a regular, fully intramolecularly H-bonded ?-helix is precluded, due to the occurrence of a tertiary amide bond every two residues. In this work, we have expanded this study to the preparation and 3D structural analysis of the heterochiral (S)-Ala/(R)-(aMe)Aze sequential peptides from dimer to hexamer. Our conformational results show that members of this series may fold in type-II ?-turns or in ?-turns depending on the experimental conditions.

Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: From hit to clinic

FFA2, also called GPR43, is a G-protein coupled receptor for short chain fatty acids which is involved in the mediation of inflammatory responses. A class of azetidines was developed as potent FFA2 antagonists. Multiparametric optimization of early hits with moderate potency and suboptimal ADME properties led to the identification of several compounds with nanomolar potency on the receptor combined with excellent pharmacokinetic (PK) parameters. The most advanced compound, 4-[[(R)-1-(benzo[b]thiophene-3-carbonyl)-2-methyl-azetidine-2-carbonyl]-(3-chloro-benzyl)-amino]-butyric acid 99 (GLPG0974), is able to inhibit acetate-induced neutrophil migration strongly in vitro and demonstrated ability to inhibit a neutrophil-based pharmacodynamic (PD) marker, CD11b activation-specific epitope [AE], in a human whole blood assay. All together, these data supported the progression of 99 toward next phases, becoming the first FFA2 antagonist to reach the clinic.

Practical preparation of enantiopure 2-methyl-azetidine-2-carboxylic acid; a γ-turn promoter

A robust and practical synthesis of each enantiomer of 2-methyl-azetidine- 2-carboxylic acid, based on the use of (S)-phenylglycinol as resolving agent, is described. This synthesis affords practical quantities of this quaternary amino acid suitably N- an

AZETIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES

Compounds are disclosed that have a formula represented by the following: These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example inflammatory conditions, infectious diseases, autoimmune diseases, diseases involving impairment of immune cell functions, cardiometabolic diseases, and/or proliferative diseases.

Substituted β-alanine derivatives as cell adhesion inhibitors

β-Alanine derivatives of Formula I are antagonists of VLA-4 and/or α4β7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of asthma, allergies, inflammation, multiple sclerosis, and other inflammatory and autoimmune disorders.